Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021

12th May 2021

This month EMA’s safety committee (PRAC) reviewed a number of safety signals related to COVID-19 vaccines. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine’s benefits and risks.

View here

Back to News Archive